Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience-Reference-Cited by-同舟云学术

Real-world outcome and healthcare costs of relapsed or refractory multiple myeloma: A retrospective analysis from the Chinese experience

Published:2016-03-01 Issue:5 Volume:21 Page:280-286
ISSN:1607-8454
Container-title:Hematology
language:en
Short-container-title:Hematology

Author:

Zhou Xin¹,Xia Jun¹,Mao Jingjue¹,Cheng Feng¹,Qian Xifeng¹,Guo Hongfeng¹

Affiliation:

1. Department of Hematology, Wuxi People's Hospital, Nanjing Medical University, Wuxi, China

Funder

Publisher

Informa UK Limited

Subject

Hematology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10245332.2015.1122259

Reference21 articles.

1. Treatment of Multiple Myeloma: A Comprehensive Review

2. International Agency for Research on Cancer. GLOBOCAN 2012: Estimated Cancer incidence and Mortality and Prevalence Worldwide in 2012. Available from: http://globocan.iarc.fr/Pages/fact_sheets_population.aspx (accessed 31 March 2015).

3. Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report

4. The cost-effectiveness of bortezomib in relapsed/refractory multiple myeloma: Swedish perspective

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Sponsorship bias in published pharmacoeconomic evaluations of national reimbursement negotiation drugs in China: a systematic review;BMJ Global Health;2023-11

2. Real-World Health Care Services Utilization Associated With the Management of Patients With Relapsed and Refractory Multiple Myeloma in Spain: The CharisMMa Study;Clinical Lymphoma Myeloma and Leukemia;2023-10

3. Real‐world utilization and healthcare costs for multiple myeloma: A retrospective analysis of patients in Singapore;eJHaem;2023-09-23

4. Healthcare resource utilization and costs among patients with relapsed and/or refractory multiple myeloma treated with proteasome inhibitors in real-world clinical practice in Germany;Journal of Medical Economics;2021-01-01

5. Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma;Leukemia & Lymphoma;2019-06-04